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Abstract
Background: Randomised controlled trials are becoming increasingly costly and time-consuming. In 2011, Royston
and colleagues proposed a particular class of multi-arm multi-stage (MAMS) designs intended to speed up the
evaluation of new treatments in phase II and III clinical trials. Their design, which controls the type I error rate and
power for each pairwise comparison, discontinues randomisation to poorly performing arms at interim analyses if
they fail to show a pre-specified level of benefit over the control arm. Arms in which randomisation is continued to
the final stage of the trial are compared against the control on a definitive time-to-event outcome measure. To
increase efficiency, interim comparisons can be made on an intermediate time-to-event outcome which is on the
causal pathway to the definitive outcome.
Methods: We adapt Royston’s MAMS design to binary outcomes observed at the end of a fixed follow-up period and
analysed using an absolute difference in proportions. We apply the design to tuberculosis (TB), an area where many
new drugs are in development, and demonstrate how it can greatly accelerate the evaluation of new TB regimens. We
use simulations to support the extensions to the methodology and to investigate the amount of bias in the estimated
treatment effects of arms in which randomisation is ceased at the first interim analysis and arms which continue to the
final stage of the trial.
Results: The proposed seamless phase II/III TB trial designs are shown to greatly reduce sample size requirements and
trial duration compared to conducting separate phase II and III trials. The bias in the estimated treatment effects for the
definitive outcome is shown to be small, especially when treatment selection is based on an intermediate outcome or
when a reanalysis is performed at the planned end of the trial after all recruited patients have completed follow-up.
Conclusions: The proposed designs are practical and could be used in a variety of disease areas. They hold
considerable promise for speeding up the evaluation of new treatments particularly in TB where many new regimens
will soon be available for testing in phase II and phase III trials.
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Background
In recent years the pace of drug development in some
disease areas has rapidly increased. Despite this, there
has been a slowdown in the rate of new therapies reach-
ing patients [1]. This is largely due to the increasing cost
and inefficiency of the drug development process and that
most new treatments have no clear benefit over standard
care. As a result, the US Food and Drug Administration
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(FDA) has called for a new ‘product development toolkit’
for improving the predictability and efficiency of clinical
trials.
Due to the acceleration in drug development it is now
more common for multiple new treatments to be simul-
taneously available for testing in clinical trials. In tuber-
culosis (TB), for example, there are currently at least
ten new or repurposed drugs in the clinical pipeline
[2-4]. Since TB is treated using a combination of drugs
rather than monotherapy, the number of regimens that
could potentially be assessed in phase II or III trials
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in the near future is vast. Evaluating each new treat-
ment against a control in separate two-arm trials will
not only require a huge amount of resources but may
deny patients access to the most effective, simplest and
shortest new regimens as early as possible. Innovative
trial designs which are able to efficiently assess multi-
ple new treatments simultaneously are therefore urgently
needed.
In discussing such an issue, Phillips et al. [5] have sug-
gested the use of the multi-arm multi-stage (MAMS)
design described by Royston et al. [6]. This particular
type of MAMS design, which controls the type I error
rate and power for each pairwise comparison, streamlines
treatment evaluation in two ways. First, comparing mul-
tiple new regimens against a single, common control arm
removes the need for separate control arms in multiple
two-arm trials and reduces the overall required sample
size. For example, comparing four experimental arms in
parallel to a single control (five-armed trial) reduces the
required sample size by 37% compared to four separate
two-arm trials if no adjustments for multiple testing are
made. In general, comparing K experimental arms to a
single control reduces the overall sample size by a fac-
tor of (K − 1)/2K compared to K separate two-arm
trials [7].
Secondly, the analysis of a MAMS trial is conducted in
stages. At the end of each stage recruitment to an experi-
mental arm is stopped if it fails to show sufficient evidence
of an advantage over the control arm (lack-of-benefit). If
an experimental arm passes the final stage of the study
then it is deemed to be superior (or non-inferior, depend-
ing on the objective) to the control. The efficiency of this
procedure can be greatly increased by using an outcome
in the intermediate stages which is observed earlier and
on the causal pathway to the final, definitive outcome
of the trial, although it does not necessarily have to be
a surrogate [8,9]. For example, the MAMS design may
be used for a seamless phase II/III trial where the inter-
mediate outcome is that used in a phase II trial while a
phase III outcome is of primary interest in the final stage.
Using an intermediate outcome in this way allows interim
analyses to be conducted sooner and so recruitment to
poorly performing arms can be stopped much earlier than
if the primary outcome of the trial was used through-
out. If a suitable intermediate outcome is unavailable then
the MAMS design may still be used, for example, as a
standalone phase II or III trial. The multi-stage aspect
of the design removes the need to recruit a fixed sample
size to all experimental arms in the trial and can fur-
ther reduce the sample size compared to multi-arm fixed
sample designs.
The sample size calculation for the MAMS design
described by Royston et al. [6] is only applicable to time-
to-event outcomes where a hazard ratio is typically the
summary statistic used to compare an experimental treat-
ment against a control. It is therefore applicable to trials
in oncology, for example, where time to an event such as
death is often used as a primary endpoint. The STAM-
PEDE trial in prostate cancer [8] for instance, uses this
particular type of MAMS design. However, if it is to be
more widely used in other disease areas then the method-
ology needs extending to other types of outcome.
In TB, a commonly used outcome measure for phase
II trials is the absolute difference in the proportion of
patients who have a negative culture status eight weeks
after commencing therapy [10-12]. In phase III, the abso-
lute difference in the proportion of patients who either
fail to respond to their allocated treatment or relapse after
completing treatment is the outcome of choice and is usu-
ally assessed 1-2 years after randomisation [13]. In this
paper we use these examples as motivation for extending
the design to binary intermediate and definitive outcomes
observed at the end of fixed follow-up periods and anal-
ysed using an absolute difference in proportions. The ben-
efits of this design and issues surrounding it are explored
and simulation studies using examples in a TB context are
used to verify the methodology and to investigate the bias
in treatment effect estimates.
Methods
Overview of proposed design
Let I denote the intermediate and D the definitive out-
come of a MAMS trial. The same null and alternative
hypotheses are used for all experimental arms to allow
interim analyses to be conducted simultaneously. The
sample size requirement is therefore the same for each
pairwise comparison in each stage and so the sample size
calculation can be developed by first considering a single
experimental arm, E, against a control, C.
For a MAMS trial with s stages, let πEi and πCi denote
the true event rates in the ith stage of the trial in an experi-
mental arm and the control arm respectively (i = 1, . . . , s).
If the same outcome is used throughout the trial (I = D)
then πEi and πCi are constant for all i. If the intermediate
and definitive outcomes differ (I = D) the values πEs and
πCs correspond to the true treatment effects for the defini-
tive outcome and πEi and πCi are constant for all i < s and
correspond to the intermediate outcome.
The null and alternative hypotheses for the true absolute
risk difference at the ith interim analysis, θi = πEi − πCi ,
are, without loss of generality,
H0 : θi ≤ θ0i , i = 1, . . . , s
H1 : θi > θ0i , i = 1, . . . , s
The value θ0i is constant for all i if the same outcome
measure is used throughout the trial (I = D). Other-
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wise θ0s corresponds to the definitive outcome and θ0i is
constant for all i < s for the intermediate outcome. In
superiority analyses, θ0i is usually taken to be 0 to repre-
sent no difference under the null hypothesis. By contrast,
non-inferiority analyses use a value of θ0i to represent that
E is slightly inferior to C under the null hypothesis.
Having specified the null and alternative hypotheses
above, the one-sided significance level, αi, and power, ωi,
for each pairwise comparison is chosen for each stage of
the trial. It is recommended to use a high power in each
stage, for example, 90% or 95%, in order to achieve high
overall power for the trial [6]. A large significance level
should be used in the first stage to allow the first interim
analysis to occur early on in the trial. Over subsequent
stages significance levels are decreased to avoid stages
becoming redundant. For trials with 6 or fewer stages
Royston et al. [6] suggest a ‘rule of thumb’ of αi = 0.5i
for stages i = 1, . . . , s − 1 and αs = 0.025 in the final
stage to mimic a conventional two-sided test at the 5%
level. However, further research by Barthel et al. [14] and
Choodari-Oskooei et al. [15] have suggested using a sig-
nificance level between 0.2 and 0.3 in the first stage to
reduce bias and error rates.
At the ith interim analysis recruitment continues to
experimental arms whose treatment effect estimate on the
intermediate outcome is significant at the 100αi% level,
otherwise consideration is given for ceasing further ran-
domisations to it. If the treatment effect estimate on the
definitive outcome is significant at the 100αs% level in the
final analysis then the experimental treatment is declared
superior to the control arm (or non-inferior, depending on
the objective).
Sample size calculation
Since each stage has its own significance level and power
we can effectively consider each stage as an independent
trial. Common formulae can therefore be used to obtain
the required sample size for each interim analysis. For
example, the required sample size for the control arm
in the ith interim analysis, nCi , can be calculated using
[16,17]
nCi =
(z1−αi + zωi)[AπCi
(
1 − πCi
)+ π1i
(
1 − π1i
)
]
A(θ1i − θ0i )2
(1)
where θ1i is the minimum effect that one would like to find
with high probability for the outcome in the ith stage (usu-
ally the minimally clinically important difference), π1i =
πCi + θ1i is the target event rate in the experimental arm
under H1, zk is the kth percentile of the standard normal
distribution and the E : C allocation ratio is A : 1 so that
A patients are randomised to each experimental arm for
every patient allocated to control.
For a MAMS trial with Ki experimental arms present in
stage i the total sample size required for the ith interim
analysis is then
ni = (1 + KiA)nCi . (2)
Consequences of a fixed follow-up period
Often in clinical trials, patients are followed-up for a set
period of time after randomisation before outcomes are
observed. For example, in phase II TB trials the endpoint
of interest is often culture status 8 weeks after randomisa-
tion. An immediate consequence of delayed observations
is that patients may withdraw or become lost-to-follow-up
before their outcome is observed. If it is likely that out-
come data will not be available for some proportion of
patients, λi, on the outcome in the ith stage of the study,
then the required sample size calculated using (2) should
be multiplied by 1/(1−λi) to maintain the desired level of
power for a complete-case analysis. It should be noted that
such an analysis assumes that missing data occur com-
pletely at random which might not be plausible, in which
case appropriate imputation techniques should be applied
[18].
For simplicity, the loss-to-follow-up rate λi is assumed
to be constant throughout the trial for each outcome. One
might normally expect a higher loss rate for D than I
as it requires a longer follow-up period, however, it may
be easier to obtain the former, particularly if it can be
ascertained from medical records (for example, death), in
which case a lower attrition rate on D may be a plausible
assumption.
Another consequence of delayed observations is that
interim analyses cannot take place as soon as the required
sample size has been recruited and randomised. Since
recruitment is continuous, the delay in obtaining data
on an outcome means that there will be patients at each
interim analysis who have been recruited to the trial
but who have yet to have their outcome observed. For
example, if the follow-up period is six months and the
recruitment rate is 100 patients per year, then an extra 50
patients will be recruited to the trial but will not com-
plete follow-up by the time of the database freeze for the
interim analysis.
These extra patients who are randomised to arms which
are subsequently dropped at the interim analysis will also
not contribute towards any future interim analyses. How-
ever, for reasons concerning bias (see ‘Results’ section)
these patients should still be followed up for their inter-
mediate and definitive outcomes and included in a final
analysis of their allocated arm against all control arm
patients randomised concurrently at the planned end of
the trial.
The delay in starting the next stage of the trial caused by
data cleaning, analysis, various committee meetings and
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changing the randomisation codes (if necessary) increases
the number of patients allocated to an arm which may
imminently be dropped from the trial. A possible solu-
tion to avoid randomising patients during this interval
and the follow-up period is to suspend recruitment once
the required sample size has accrued and then recom-
mence it at the start of the next stage. However, this
is not recommended since it is likely to prolong the
duration of the trial by slowing the overall recruitment
rate [5].
Calculating the stage durations
The total expected delay, γi, between recruiting the last
of the ni patients required for the ith interim analysis and
the beginning of the next stage of the trial incorporates
the follow-up period for the outcome plus the additional
delays caused by the analysis. Denoting by Ni the total
number of patients recruited to the arms remaining in
the study by the end of stage i, the number of patients
that need to be recruited during stage i for the upcoming
interim analysis, n˜i, is
n˜i = ni − AKi + 1AKi−1 + 1Ni−1(1 − λi)
where N0 = 0 and Ki is the number of active experimen-
tal arms in the ith stage of the study. It follows that the
duration of stage i is
di = n˜iri(1 − λi) + γi
where ri is the overall recruitment rate in the ith stage
(assumed to be constant within each stage).
The cumulative number of patients allocated to all treat-
ment arms still recruiting at the end of each intermediate
stage is then
Ni = ridi + AKi + 1AKi−1 + 1Ni−1 i = 1, . . . , s − 1.
In the final stage recruitment to the trial may be ter-
minated as soon as Ns = ns/(1 − λi) patients have been
allocated to the remaining treatment arms. It would not
be necessary to continue recruitment beyond this point,
since there are no more analyses planned beyond the final
analysis.
The stage end-times, ti, are obtained by summing the
durations of all preceding stages; ti = ∑ik=1 dk . These
values are particularly useful as they roughly predict
when interim analyses will occur and so help to organise
data monitoring and trial steering committee meetings in
advance.
Probability of passing each stage
Using similar formulae to Royston et al. [6] the probabil-
ities of an experimental arm passing the first i stages of a
MAMS trial are
Ai = i(zα1 , . . . , zαi ;R0i ) under H0
	i = i(zω1 , . . . , zωi ;R1i ) under H1
where i(;Rhi ) is the i-dimensional multivariate normal
distribution function with correlation matrix Rhi (h =
0, 1). The (j, k)th entry of Rhi is the correlation between
the treatment effects in stages j and k under hypothesis
Hh. The calculation of these correlations is outlined in the
appendix.
Clearly, A1 = α1 and 	1 = ω1. The most important
values are As and 	s which are the overall type I error
rate, α, and power, ω, respectively for a single experimen-
tal arm compared to the control. Note that here we have
only calculated the pairwise type I error rate and power—
the issue of familywise error rates for trials with multiple
experimental arms is raised in the discussion.
Other values of interest, particularly in a seamless phase
II/III design, are As−1 and 	s−1 which denote the prob-
ability of continuing recruitment to an arm in the final
(phase III) stage of the trial under H0 and H1 respectively.
Phase III trials are often resource intensive and lengthy
and the same may be true for the final stage of a MAMS
trial if the intermediate and definitive outcomes differ.
Therefore it is important to have a reasonably small value
of As−1 and a large value of	s−1 to increase the chance of
only recruiting patients to effective treatments in the final
stage.
As shown in the appendix, the calculation of As and 	s
when I = D requires estimates of either the probability
of a patient experiencing both outcomes or the probabil-
ity of experiencing the definitive outcome given they have
had the intermediate outcome (positive predictive value,
PPV). The latter is arguably easier to specify as it only
requires an assumption for a single outcome,D (given that
I has occurred), rather than two (both I and D). As the
correlations between treatment effects, and therefore As
and 	s, increase as either of these probabilities tend to 1,
we recommend slightly overestimating them to obtain a
conservative estimate of the pairwise type I error rate.
Application to tuberculosis
To illustrate how this design might be applied and assess
the benefits of the MAMS design in a TB setting we
used the methodology above to calculate the sample size
for phase II and seamless phase II/III two-arm two-
stage TB trials. Seamless designs are an effective tool
for streamlining treatment evaluation as they remove the
long interlude between phases which is required for pre-
senting the phase II results and for designing, approving
Bratton et al. BMCMedical ResearchMethodology 2013, 13:139 Page 5 of 14
http://www.biomedcentral.com/1471-2288/13/139
and funding the phase III trial. Furthermore, by reusing
phase II patients in the analysis of the phase III out-
come, seamless designs offer greater efficiency over the
traditional approach of conducting phase II and III trials
separately [19].
The phase II two-arm two-stage designs were based
upon a recent study by Dorman et al. [10] that sub-
stituted moxifloxacin for isoniazid in the standard TB
regimen during the intensive phase (first two months) of
treatment. The outcome in this study was culture status
(a marker for whether a patient has TB or not) 8 weeks
after randomisation and was also used as the basis for
the intermediate outcome in the seamless phase II/III
designs. The phase III aspect was based on the ongoing
REMox TB trial (controlled comparison of two moxi-
floxacin containing treatment shortening regimens in pul-
monary tuberculosis) that investigates the effect of two
four month regimens against the standard six month regi-
men on relapse rates 18 months after randomisation [20].
This trial uses a Bonferroni-adjusted one-sided signifi-
cance level of 1.25% for each treatment arm to ensure the
overall type I error rate is no higher than 2.5%. For this
example we considered only one experimental arm from
REMox and thus used a one-sided significance level of
2.5%. The designs of these standalone phase II and phase
III trials are summarised in Table 1.
Examples of two-arm two-stage phase II and phase II/III
TB trials were generated using a conventional significance
level (2.5%) and power (90%) in the final stage. Signifi-
cance levels of 20% and 50% and powers of 90% and 95%
were explored in the first stage. Delays of 4 and 14 weeks
for observing a patient’s culture status after randomisation
Table 1 Design parameters for phase II and III TB trials
Design Study
Overall*
Parameter Phase II Phase III
Primary outcome
Negative Non-
culture status failure/relapse
Follow-up length 8 weeks** 18 months**
Significance level (1-sided) 2.5% 2.5% 0.1%
Power 80% 85% 68%
Control arm event rate 75% 90%
Treatment effect under H0 0% -6% (NI margin)
Target treatment effect (H1) 13% 0%
Allocation ratio (E : C) 1:1 1:1
Attrition rate 15% 20%
Required sample size*** 320 1122 1442
Design parameters for a phase II (based on Dorman et al. [10]) and a phase III
(based on REMox [20]) TB trial. *Calculated assuming independence between
trials. **An additional 6 week delay is typically required to determine culture
status. ***Sample sizes estimated using equations (1) and (2). NI = non-inferiority.
were used to explore their effect on the efficiency of a trial.
The latter was chosen as it is the current delay in observ-
ing a patient’s culture status after randomisation due to
the 8 week follow-up period plus 6 week wait for detect-
ing absence of TB (in liquid medium). A 4 week delay was
also chosen as it is not yet certain whether culture sta-
tus at 8 weeks is an appropriate intermediate outcome for
long-term relapse, and observing it after 4 weeks may be
more suitable. Furthermore, the 6 week wait is unlikely to
exist in future as techniques for immediate detection of
TB are developed [21] and so observing status at 4 weeks
may represent the shortest possible delay for this outcome.
Examples of two-arm two-stage phase II and phase II/III
TB trial designs based on these parameters are shown in
Tables 2 and 3 respectively and discussed in the ‘Results’
section.
The efficiency of each design was measured by its
expected sample size (ESS), that is, the mean number of
patients recruited to the trial before it is terminated [22],
calculated under the null hypothesis. ESS was compared
between designs with roughly similar overall operating
characteristics to determine which is likely to require
fewer resources when the experimental treatment is inef-
fective. For a single-stage trial, such as those in Table 1,
the ESS is equal to the overall sample size since there is
no opportunity for stopping before the planned end of
the trial (except perhaps in extreme circumstances such as
overwhelming efficacy of an arm).
To calculate the overall operating characteristics in the
seamless designs an estimate of the positive predictive
value, that is, the probability of a patient not relapsing or
being classed as a treatment failure given that they have
a negative culture, was obtained from a meta-analysis by
Horne et al. [23] who estimated it to be 95% (95% CI
(95%, 96%)) for cultures taken at 2 months. This value
was assumed to be the same under H0 and H1 for each
intermediate outcome.
Simulation study
Performing an analysis in a MAMS trial which ignores
the stopping guidelines for lack-of-benefit may result in
biased treatment effect estimates [15]. Choodari-Oskooei
et al. [15] investigated the extent of this bias for two-arm
multi-stage trials with time-to-event outcomes. For arms
stopped at the first interim analysis for lack-of-benefit
they showed that on average the estimated treatment
effects appeared slightly less effective than their corre-
sponding true values. However, the bias was markedly
reduced by continuing to follow-up patients on the inter-
mediate and definitive outcomes and reanalysing the data
at the planned end of the trial. For truly effective arms,
they showed that the bias in the estimated treatment
effects on the definitive outcome at the final stage analysis
was of no practical importance.
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Table 2 Examples of two-arm two-stage phase II TB trials
Design Stage (i) αi ωi
Length of f/u = 4 weeks Length of f/u = 8 weeks*
ρ Ai i
Fixed
ni Ni ti ESS |H0 ni Ni ti ESS |H0 sample size
(i)
1 0.5 0.90 56 96 0.48
262
56 134 0.67
281 0.39
0.500 0.900
360
2 0.025 0.90 364 428 2.30 364 428 2.49 0.021 0.826
(ii)
1 0.5 0.95 94 140 0.70
284
94 178 0.89
303 0.51
0.500 0.950
398
2 0.025 0.90 364 428 2.30 364 428 2.49 0.023 0.870
(iii)
1 0.2 0.90 156 214 1.07
257
156 252 1.26
287 0.65
0.200 0.900
381
2 0.025 0.90 364 428 2.30 364 428 2.49 0.020 0.843
(iv)
1 0.2 0.95 214 282 1.41
311
214 320 1.60
342 0.77
0.200 0.950
414
2 0.025 0.90 364 428 2.30 364 428 2.49 0.023 0.883
Characteristics of two-arm two-stage TB trials where I = D = culture status observed 4 or 14 weeks after randomisation. The fixed sample sizes correspond to fixed
sample designs with pairwise alpha A2 and power	2 . Key: for stage i, αi = significance level, ωi = nominal power, ni = total sample size required for analysis i, Ni =
cumulative number of patients recruited by the end of stage i, ti = predicted timing (in years) of the end of stage i assuming a recruitment rate of 200 patients/year,
ESS|H0 = expected sample size under the null hypothesis, ρ = correlation between stages, Ai = probability of passing stage i under H0,	i = probability of passing
stage i under H1. *Plus an additional 6 week delay to determine culture status.
In the time-to-event case, interim analyses occur when
a pre-specified number of events have been observed in
the control arm. In arms in which recruitment is stopped
early there is scope for continuing to follow-up patients
who have not yet experienced the event(s) of interest
and including them in a reanalysis at the planned end
of the trial to obtain a less biased estimate of the treat-
ment effect. This is also applicable when outcomes are
observed at the end of a fixed follow-up period since
not all patients will have had both their intermediate and
definitive outcomes observed by each interim analysis.
A simulation study was conducted using the two-stage
phase II and phase II/III TB trial designs shown in Tables 2
and 3 respectively, to quantify the bias of treatment effects
estimated on the definitive outcome at:
(a) The first interim analysis in arms which are not
continued to the second stage
(b) A reanalysis of the same arms (against all control arm
patients recruited concurrently) after intermediate
and definitive outcome data have been obtained from
all patients
(c) The final stage analysis of all arms which pass all
intermediate stages
Phase II/III designs in which the follow-up period for I
was 4 weeks rather than the current 14 weeks (designs not
shown) were also used to investigate the effect of follow-
up length in (b).
In addition to bias, the proportion of arms for which
recruitment is stopped at the first interim analysis and the
proportion which continue recruiting to the final stage of
the trial, as well as the pairwise type I error rate, power and
correlation between stages were determined in the sim-
ulations and compared to their corresponding calculated
values.
Table 3 Examples of two-arm two-stage phase II/III TB trials
Design Stage(i) αi ωi ni Ni ti ESS |H0 ρ|H0 ρ|H1 Ai i
(v)
1 0.5 0.90 56 134 0.67
723 0.10 0.08
0.500 0.900
2 0.025 0.90 1050 1312 3.84 0.015 0.813
(vi)
1 0.5 0.95 94 178 0.89
745 0.12 0.11
0.500 0.950
2 0.025 0.90 1050 1312 4.00 0.015 0.857
(vii)
1 0.2 0.90 156 252 1.26
464 0.16 0.14
0.200 0.900
2 0.025 0.90 1050 1312 4.28 0.008 0.815
(viii)
1 0.2 0.95 214 320 1.60
518 0.19 0.16
0.200 0.950
2 0.025 0.90 1050 1312 4.54 0.009 0.858
Characteristics of two-arm two-stage TB trials where I = culture status observed 14 weeks after randomisation and D = relapse status at 18 months. Key: for stage i, αi =
significance level, ωi = nominal power, ni = total sample size required for analysis i, Ni = cumulative number of patients recruited by the end of stage i, ti = predicted
timing (in years) of the end of stage i, ESS|H0 = expected sample size under the null hypothesis, ρ|Hh = correlation between stages under hypothesis Hh, Ai =
probability of passing stage i under H0,	i = probability of passing stage i under H1.
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For each design shown in Tables 2 and 3, the bias associ-
ated with the following four pairs of underlying treatment
effects for the culture status (CS) and relapse outcomes (R)
were investigated in the simulations:
A. θCS = −5%, θR = −10% (treatment effects worse
than those under H0)
B. θCS = 0%, θR = −6% (treatment effects under H0
(see Table 1))
C. θCS = 8%, θR = −3% (treatment effects between
those under H0 and H1)
D. θCS = 13%, θR = 0% (treatment effects under H1 (see
Table 1))
By assessing bias in scenarios (a), (b) and (c) for this
variety of treatment effects, recommendations can be
made for designing multi-stage trials which reduce bias,
thus improving the accuracy of treatment effect esti-
mates which might be used, for example, in future meta-
analyses, policy-making decisions or the design of future
trials.
Simulationmethods
To perform the bias assessment and assess the accuracy
of the calculation of the pairwise operating characteris-
tics, individual patient data were simulated for each phase
II and phase II/III design under treatment effects A-D.
In each case 40,000 replicates were generated to estimate
pass/fail rates to an accuracy of at least 0.5% at the 5%
significance level. For each patient, missing value indica-
tors for the I and D outcomes were drawn from Bernoulli
distributions with parameters derived from Table 1. In
the designs where I = D the probability of observing
the definitive outcome was not conditional on observ-
ing the intermediate outcome. Although this reduces the
correlation between stages compared to the calculation
given in the appendix where all patients with a missing
intermediate outcome are also assumed to have a missing
definitive outcome, these different assumptions will indi-
cate the robustness of the calculation of the overall type I
error rate and power.
Patient outcomes were drawn from Bernoulli distribu-
tions with control arm event rates derived from Table 1.
The underlying event rates for experimental arms with
underlying effects A-Dwere found by adding on the corre-
sponding treatment effects shown above. Since the phase
III outcome (relapse) is dependent on culture status, the
event rate will differ according to whether a patient’s cul-
ture status is positive (CS = 0), negative (CS = 1) or miss-
ing. The positive predictive value (PPV=P(R = 1|CS = 1))
is the relapse event rate for patients with a positive culture
status and the estimate from Horne et al. (95%) [23] was
assumed for all arms. The probability P(R = 1|CS = 0)
for each treatment arm was then found by rearranging the
formula
P(R = 1) = P(R = 1|CS = 1)P(CS = 1)
+ P(R = 1|CS = 0)P(CS = 0)
Unconditional event rates were used for patients with
missing intermediate outcomes.
When simulating each trial, analyses were triggered
once the pre-determined number of control arm patients
had their outcome of interest observed. The pairwise
type I error rate and power for each design was cal-
culated as the proportion of arms simulated under H0
(treatment arm B) and H1 (treatment arm D) respectively
which passed all stages of the trial. For each underly-
ing treatment effect in each design, the absolute bias in
scenarios (a), (b) and (c) was calculated as the average
deviation of all treatment effect estimates from the true
value.
Results
Examples of phase II TB trials
Table 2 summarises the sample sizes and durations of
phase II two-arm two-stage trials which use culture sta-
tus at 4 or 8 weeks of follow-up as the primary endpoint
for both the intermediate and definitive outcomes. A con-
stant recruitment rate of 200 patients/year was assumed
in both stages.
The results show that the maximum sample sizes of the
two-stage designs shown in Table 2 are higher than the
corresponding fixed sample sizes, however, their expected
sample sizes are much lower as they allow recruitment to
be stopped early if the experimental treatment does not
show sufficient benefit at the first stage. Increasing the
power in the first stage reduces the difference between
the maximum and fixed sample sizes, however, this also
increases the expected sample sizes due to a larger first
stage. Thus, a balance needs to be found between the two
measures. As expected, the correlation between stages
increases as the gap between analyses decreases, however,
this only marginally increases the type I error rate and
power.
Although designs (ii) and (iv) have similar overall oper-
ating characteristics, the design which uses a first stage
significance level of α1 = 50% (design (ii)) has a much
smaller expected sample size. On the other hand, designs
(i) and (iii) also have similar overall operating character-
istics but are approximately equally efficient. Unsurpris-
ingly, the ESS is smaller when using a shorter follow-up
period since fewer patients are recruited during the first
stage of the trial. All two-stage designs have the same
maximum sample size as they use the same final stage
operating characteristics.
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There appears little advantage in using these two-stage
designs over a single-stage design for two-arm phase II TB
trials, however, if multiple treatments are to be evaluated
in a single trial then stopping guidelines for lack-of-benefit
will become much more useful. Due to the current length
of follow-up for culture status (8 weeks) and short length
of phase II trials, using more than two-stages is unlikely to
improve efficiency.
Examples of seamless phase II/III TB trials
Examples of seamless two-stage TB trials are presented in
Table 3. A constant recruitment rate of 200 patients/year
was assumed for the intermediate (phase II) stage and a
much higher recruitment rate of 800 patients/year was
used for the second (phase III) stage. Under these assump-
tions the maximum duration of each design is no longer
than 5 years. If similar recruitment rates are assumed
for the fixed sample designs shown in Table 1 then the
maximum duration of conducting both trials separately is
approximately 8.5 years assuming a modest delay between
phases of 3 years. Furthermore, the overall power of the
seamless designs (over 80%) is much higher than that for
conducting trials separately (68%) and maximum sample
sizes are over 100 patients lower.
The between-stage correlations in these designs are
much lower than those in the phase II designs for two rea-
sons. Firstly, the positive predictive value is effectively 1
in designs with I = D (see Appendix) whereas the seam-
less designs use a slightly lower value (0.95). Secondly, the
interim and final analyses are much further apart in terms
of sample size than in the phase II designs, which fur-
ther reduces the correlation. Although not problematic,
the immediate consequence of lower between-stage cor-
relation is a reduction in both the pairwise type I error rate
and power, and so the stagewise operating characteristics
may have to be increased to achieved the desired level for
each measure.
A downside of the seamless designs presented in Table 3,
as illustrated by the high ESS, is that ineffective arms
have a reasonable chance of proceeding to the final stage
of the trial due to the high significance level used in
the first stage. To combat this, the large gap between
the first and final analyses means that an extra inter-
mediate stage could be added to the trial. For exam-
ple, adding a second intermediate stage with 95% power
and a 10% significance level to design (vi) in Table 3
reduces the ESS to 377 with only a 3% reduction in
overall power. This loss can be recovered by slightly
increasing the stagewise powers. Identifying MAMS
designs which maintain the overall operating characteris-
tics but have desirable properties such as minimising the
expected or maximum sample sizes is an area of ongoing
research.
Clearly there is much more benefit in using the MAMS
design for seamless phase II/III TB trials than for phase
II alone. We have demonstrated the savings in time and
resources that can be achieved in using seamless two-arm
two-stage trials over conducting each phase separately.
For multi-arm multi-stage seamless trials, the savings will
potentially be much greater compared to conducting sep-
arate phase II and phase III trials for each experimental
treatment.
Results of simulation study
Table 4 shows that the overall type I error rate, power and
correlation between stages estimated from the simulations
of the designs shown in Tables 2 and 3 agree very well with
the corresponding calculated values. As expected, when
I = D the correlation between stages estimated from the
simulations is slightly lower than the calculated values,
however, this leads to only a negligible difference between
the overall type I error rates and powers showing that the
calculation is robust to the degree of dependence between
observing each outcome.
Bias in arms dropped at the first analysis
Table 5 summarises the simulation results for the pro-
portion of arms dropped at the end of the first stage and
the absolute bias in their treatment effect estimates on
the definitive outcome at the interim analysis and after all
remaining patients have completed follow-up. The pro-
portion of arms dropped under H0 (treatment effect B)
and H1 (treatment effect D) is as expected given the
significance level and power in this stage.
The results show that, on average, treatment effects
are underestimated in arms which do not show suffi-
cient benefit at the first interim analysis. When I = D
the absolute bias in such arms is particularly high when
a high significance level (50%) and relatively low power
(90%) is used (design (i) in Table 2), in other words,
the earlier the interim analysis occurs. In this design
the magnitude of the absolute bias is over 9% under
H0. However, the bias is markedly reduced in a reanal-
ysis after all remaining patients have had their outcome
observed, with a greater reduction in bias when using a
longer follow-up period or, more generally, when more
patients can be added to the reanalysis. In this particu-
lar example, the magnitude of the absolute bias under H0
decreases from 9.5% to 6.5% for 4 week follow-up and to
4.6% if outcome observation is delayed by 14 weeks after
randomisation.
When using a relatively low significance level in the
first stage (e.g. 20%) the bias is of no practical importance
in arms which are likely to be stopped at that analysis,
particularly after follow-up is complete. When I = D,
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Table 4 Correlations, type I error rates and powers obtained from simulation compared to calculated values
Design α1 ω1
From calculation From simulation
ρ|H0 ρ|H1 α ω ρˆ|H0 ρˆ|H1 αˆ ωˆ
I = D = culture status
(i) 0.50 0.90 0.39 0.39 0.021 0.826 0.38 0.38 0.021 0.828
(ii) 0.50 0.95 0.50 0.50 0.023 0.870 0.50 0.50 0.024 0.872
(iii) 0.20 0.90 0.65 0.65 0.020 0.843 0.64 0.65 0.019 0.847
(iv) 0.20 0.95 0.76 0.76 0.023 0.883 0.76 0.76 0.023 0.885
I= culture status, D = relapse
(v) 0.50 0.90 0.10 0.08 0.015 0.813 0.07 0.06 0.014 0.809
(vi) 0.50 0.95 0.12 0.11 0.015 0.857 0.10 0.09 0.015 0.854
(vii) 0.20 0.90 0.16 0.14 0.008 0.815 0.12 0.11 0.008 0.811
(viii) 0.20 0.95 0.19 0.16 0.009 0.858 0.15 0.12 0.008 0.858
Overall type I error rates, powers and correlations between stages obtained from simulations of designs (i)-(viii) in Tables 2 and 3. Key: α1 = stage 1 significance level,
ω1 = stage 1 power, ρ|Hh = correlation between stages under hypothesis Hh, α = overall type I error rate, ω = overall power. Hats indicate values estimated from
simulations.
Table 5 Absolute bias in arms dropped at the first interim analysis
I = D = culture status I = culture status, D = relapse
α1
Treatment % stop
True θD
Bias on D Bias on D after f/u
True θD
Bias on D after f/u
arm at at interim Length of f/u Length of f/u Length of f/u Length of f/u
stage 1 analysis on I = 4 wks on I = 8 wks* on I = 4 wks on I = 8 wks*
Stage 1 power ω1 = 90%
0.5
A 65 -5% -6.9% -4.7% -3.2% -10% -1.4% -1.0%
B 49 0% -9.5% -6.5% -4.6% -6% -1.7% -1.3%
C 23 8% -14.6% -9.8% -7.0% -3% -2.7% -1.9%
D 10 13% -18.2% -12.3% -8.8% 0% -3.0% -2.1%
0.2
A 94 -5% -0.9% -0.8% -0.7% -10% -0.2% -0.2%
B 80 0% -2.6% -2.1% -1.9% -6% -0.5% -0.5%
C 35 8% -6.9% -5.9% -5.0% -3% -1.6% -1.4%
D 10 13% -10.7% -9.2% -7.7% 0% -2.2% -2.0%
Stage 1 power ω1 = 95%
0.5
A 70 -5% -4.6% -3.6% -2.8% -10% -1.0% -0.9%
B 49 0% -7.3% -5.6% -4.5% -6% -1.5% -1.2%
C 17 8% -12.6% -9.8% -7.6% -3% -2.7% -2.1%
D 5 13% -16.3% -12.9% -9.9% 0% -3.4% -2.7%
0.2
A 95 -5% -0.6% -0.6% -0.5% -10% -0.2% -0.2%
B 80 0% -2.1% -1.8% -1.6% -6% -0.5% -0.4%
C 27 8% -6.7% -6.0% -5.3% -3% -1.7% -1.5%
D 5 13% -10.8% -9.6% -8.4% 0% -2.3% -2.1%
Simulation results showing the proportion of trials stopped at the first interim analysis and the absolute bias for such arms in the estimated treatment effect on D at
the interim analysis and after all remaining patients have been followed up. Key: α1 = significance level in stage 1, θD = underlying treatment effect on the definitive
outcome. *Plus an additional 6 week delay to determine culture status.
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the bias in the treatment effect estimates for D is much
lower thanwhen the same outcome is used throughout the
trial, even when using a high significance level in the first
stage.
Bias in arms reaching the final analysis
Table 6 shows that treatment effects estimated at the final
planned analysis of the trial are overestimated on average,
although the bias is generally not as large as it is for arms
dropped at the first analysis. The results suggest that bias
decreases the further the interim analysis is in terms of
sample size from the final analysis (i.e. as the correlation
between stages decreases) and when the chance of pro-
ceeding to the final stage of the trial is higher, as is the case
for effective arms.
In the examples used in Table 6 the bias is practically
zero in all cases when I = D, even for ineffective arms.
This is due to the very low correlation between stages in
these designs (roughly 0.1). However, even when the cor-
relation is higher, for example when I = D, the bias is still
approximately zero for arms which are likely to proceed
to the final stage. Bias is higher for ineffective arms, how-
ever, in a well-designed MAMS trial such arms should
have little chance of reaching the final stage.
Discussion
We have successfully adapted the MAMS design ini-
tially developed by Royston et al. [6] to binary outcomes
which are observed at the end of a fixed follow-up
period and analysed using an absolute difference in pro-
portions. Throughout this paper we have used TB as
an example of a disease area where a MAMS approach
could dramatically speed up treatment evaluation com-
pared to the traditional approach of separate, two-arm
phase II and III trials. Savings in time and resources
are particularly large when using the MAMS design
to incorporate both phase II and phase III into a sin-
gle seamless trial, however, savings are still likely to be
made when using it to design multi-arm phase II tri-
als. Many new and repurposed drugs are currently in
clinical development for TB and so a huge number of
new regimens are likely to be available for testing in
Table 6 Absolute bias in arms reaching the final analysis
α1
Treatment
θD
ω1 = 0.90 ω1 = 0.95
arm % Pass E(θˆD) bD %Pass E(θˆD) bD
I = D = culture status at 8 weeks
0.5
A -5% 35 -3.1% 1.9% 29 -2.2% 2.8%
B 0% 51 1.4% 1.4% 50 1.8% 1.8%
C 8% 78 8.6% 0.6% 83 8.7% 0.7%
D 13% 90 13.3% 0.3% 95 13.2% 0.2%
0.2
A -5% 6 0.9% 5.9% 5 2.4% 7.4%
B 0% 20 4.2% 4.2% 20 4.8% 4.8%
C 8% 65 9.5% 1.5% 73 9.5% 1.5%
D 13% 90 13.5% 0.5% 95 13.4% 0.4%
I = culture status at 8 weeks, D = relapse
0.5
A -10% 35 -9.8% 0.2% 30 -9.7% 0.3%
B -6% 51 -5.9% 0.1% 51 -5.8% 0.2%
C -3% 77 -3.0% 0.0% 83 -2.9% 0.1%
D 0% 90 0.0% 0.0% 95 0.0% 0.0%
0.2
A -10% 6 -9.4% 0.6% 5 -9.3% 0.7%
B -6% 20 -5.6% 0.4% 20 -5.5% 0.5%
C -3% 65 -2.9% 0.1% 73 -2.9% 0.1%
D 0% 90 0.0% 0.0% 95 0.0% 0.0%
Simulation results showing the proportion of trials which continue to the final stage of the trial (% pass) and the absolute bias in the estimated treatment effect on D
at the final analysis. Key: θD = underlying treatment effect on the definitive outcome, α1 = significance level in stage 1, ω1 = nominal power in stage 1, E(θˆD) = average
treatment effect on the definitive outcome in the final stage, bD = E(θˆD) − θD = bias in the average treatment effect estimate on the definitive outcome in the final
stage.
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phase II and III trials in the near future. Evaluating
them in separate, single stage trials will not only be
costly but will prolong the discovery of a simpler and
shorter effective regimen by decades. Use of novel trial
designs such as the MAMS design is therefore urgently
required.
Further work is needed to determine the best interme-
diate outcome for long-term relapse before the MAMS
design described here can be used to evaluate TB treat-
ments in a seamless phase II/III trial. The methods
used by Barthel et al. [14], who evaluated the perfor-
mance of the MAMS design for time-to-event outcomes
in four cancer trials, could be applied to past TB tri-
als. If the rate at which trials are incorrectly stopped
for lack-of-benefit on culture status at eight weeks is
high then other intermediate outcomes will need con-
sidering, such as culture status at other time points.
Another candidate for the intermediate outcome is time
to culture conversion, which is increasingly being used
in phase II trials and is arguably a more reliable surro-
gate endpoint than culture status at a single time point
[24]. Although surrogacy is not a requirement for an
intermediate outcome it is likely that a surrogate out-
come will be a reliable choice. An ongoing trial con-
ducted by the PanACEA consortium with a MAMS
design (ClinicalTrials.gov identifier NCT01785186) is
using this endpoint but since this is a phase II trial
the definitive outcome is also time to culture conver-
sion. Incorporating this outcome into a MAMS design
with a binary definitive outcome will require further
extensions to the methodology which we are currently
developing.
The amount of bias likely to be generated in various
examples of phase II and phase II/III TB trials was inves-
tigated and was shown to be of no practical importance
in arms reaching the final analysis, particularly in effective
arms or when treatment selection is based on an inter-
mediate outcome. In general, the bias at the final analysis
increases as the treatment effects estimated at each stage
become more correlated. This is caused by having short
stage durations in which only a small amount of new
data can be collected. Ensuring that stages are adequately
spaced is not only practical from the perspective of every-
one involved in the trial but it will also limit the amount
of bias likely to be generated.
As shown by Choodari-Oskooei et al. [15], we also
found that having an early first interim analysis increased
the bias of treatment effect estimates in arms dropped
at this analysis, particularly when the intermediate and
definitive outcomes were identical. Bias was markedly
reduced in a reanalysis after all patients had completed
follow-up. It should be noted, however, that the aver-
age treatment effect in arms which are stopped early for
lack-of-benefit (i.e. are statistically non-significant) will
necessarily appear less effective than their true value [25].
Freidlin and Korn [26] suggest that the most appropri-
ate comparator for the x% of trials stopped at the first
interim analysis is the average treatment effect estimate of
the same outcome in the corresponding x% most extreme
trials in the fixed sample-size design (the design that has
no interim analyses). When taking this into consideration
the bias estimates in Table 5 are nearly halved (data not
shown).
A calculation for the overall type I error rate for a sin-
gle experimental armwas described, thus allowing control
of this measure. However, in a multi-arm trial it may be
more important to control the familywise type I error rate
(FWER), that is, the probability of rejecting at least one
true null hypothesis at the end of the trial. Freidlin et al. [7]
argue that this decision depends on the clinical questions
that the trial is addressing. For example, if a multi-armed
trial was used purely for efficiency reasons and the inter-
pretation of the results of one arm has no influence over
the results of other arms then they argue that no control
of the FWER needs to be made. On the other hand, if in
some way the treatment arms are related, such as different
doses or schedules of the same treatment, then multiplic-
ity adjustment should be made. Others have said that if a
multi-arm design is to be used in a confirmatory trial then
FWER control is a requirement [27,28].
For the MAMS design described here, a crude method
for ensuring that the FWER is no higher than some pre-
specified level is to apply a Bonferonni correction to the
pairwise type I error rate: i.e. in a trial with K experimen-
tal arms, a pairwise α equal to FWER/K could be used.
However, such a correction can be too conservative and
may result in a trial which is much larger than might be
necessary, thus losing efficiency. More accurate methods
for controlling the FWER in the strong sense (i.e. under
any parameter configuration) are therefore required and is
a subject of ongoing research. Alternatively, other MAMS
designs which allow stopping for lack-of-benefit and
control the FWER are available [29-32].
Conclusions
The methodology presented in this paper is aimed at
reducing the amount of time and resources required to
obtain reliable results from clinical studies. A Stata pro-
gram for designing MAMS trials with binary outcomes is
available from the authors upon request. Further work is
ongoing into finding MAMS designs which are the most
efficient in terms of the expected or maximum sample size
or a mixture of the two for a given overall pairwise or
familywise type I error rate and power. In TB, the MAMS
design will have the greatest impact in phase II/III seam-
less designs, however, considerable savings are also likely
to be made in other disease areas.
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Appendix
Appendix: Estimating the correlation matrices
Before Ai and 	i can be calculated the correlation
matrices, R0i and R1i , whose (j, k)th entries are the correla-
tions between the treatment effects in stages j and k under
H0 andH1 respectively, are required.We begin with a gen-
eral case where the binary outcomes of interest in stages j
and k are different. Suppose outcome X is the outcome of
interest in stage j and outcome Y is of interest in stage k
with j < k and denote the observed treatment effects by
θˆj = πˆEj − πˆCj and θˆk = πˆEk − πˆCk respectively.
If πhi = πCi + θhi is the target experimental arm event
rate under hypothesis Hh then the standard deviation of
θhi in its normal approximation is
σ hi =
√√√√πhi
(
1 − πhi
)
AnCi
+
πCi
(
1 − πCi
)
nCi
Assuming success rates between treatment arms are
independent, the correlation between θˆj and θˆk under
hypothesis Hh (h = 0, 1), denoted by ρh(j,k), is
ρh(j,k) =
Cov(θˆj, θˆk)
σ hj σ
h
k
=
Cov
(
πˆhj − πˆCj , πˆhk − πˆCk
)
σ hj σ
h
k
=
Cov
(
πˆhj , πˆhk
)
+ Cov
(
πˆCj , πˆCk
)
σ hj σ
h
k
Denote by XCm and YCm the observed X and Y out-
comes respectively for the mth patient in the control
arm (XCm,YCm ∈ {0, 1}) where XCm is observed during or
before stage j and YCm is observed during or before stage
k (j < k). The covariance between the control arm event
rates in stage j on the X outcome and stage k on the Y
outcome is
Cov(πˆCj , πˆCk ) = Cov
⎛
⎜⎝ 1nCj
nCj∑
l=1
XCl ,
1
nCk
nCk∑
m=1
YCm
⎞
⎟⎠
= 1
nCj nCk
nCj∑
l=1
nCk∑
m=1
Cov
(
XCl ,YCm
)
= 1
nCj nCk
nCj∑
l=1
nCk∑
m=1
{
E(XCl YCm) − E(XCl )E(YCm)
}
Assuming observations from different patients are inde-
pendent implies E(XCl YCm) = E(XCl )E(YCm) if l = m and
so
Cov(πˆCj , πˆCk ) =
1
nCj nCk
nCj∑
l=1
(
E(XCl YCl ) − E(XCl )E(YCl )
)
since j < k
= 1
nCj nCk
nCj∑
l=1
(
πC(j,k) − πCj πCk
)
= 1
nCk
(
πC(j,k) − πCj πCk
)
where πC
(j,k) is the probability of a patient experiencing
both the X and Y outcomes in the control arm. A similar
argument for the covariance of event rates between stages
in an experimental arm under Hh gives
Cov
(
πˆEj , πˆEk
)
= 1
AnCk
(
πh(j,k) − πhj πhk
)
.
It follows that
ρh(j,k) =
(
πh
(j,k) − πhj πhk
)
+ A
(
πC
(j,k) − πCj πCk
)
AnCk σ hj σ hk
(3)
The values πC
(j,k) and πh(j,k) may be estimated from prior
knowledge or, if estimates of the positive predictive value
in each arm are available, that is, the probability of a
patient having a Y event given that they have had an X
event, then from the definition of conditional probability
πC(j,k) = P
(
YCm = 1|XCm = 1
)
πCj
and
πh(j,k) = P
(
Yhm = 1|Xhm = 1
)
πCj .
If the outcomes of interest in stages j and k are the same
then equation (3) simplifies. Clearly the positive predictive
value is now 1 and so πC
(j,k) = πCj and πh(j,k) = πhj . Then
ρh(j,k) =
(
πhj − (πhj )2
)
+ A
(
πCj − (πCj )2
)
AnCk σ hj σ hk
=
πhj
(
1 − πhj
)
+ AπCj
(
1 − πCj
)
AnCk σ hj σ hk
=
nCj
(
σ hj
)2
nCk σ hj σ hk
=
√√√√nCj
nCk
(4)
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since underlying treatment effects are assumed to be con-
stant throughout the trial. Note that these correlations are
the same under H0 and H1 (ρ0(j,k) = ρ1(j,k)).
The entries, ρh
(j,k), below the main diagonal of the cor-
relation matrices can now be calculated using (3) for the
correlations between the intermediate and final outcomes
and (4) for the correlations between the intermediate out-
come in different stages. Since each matrix is symmetric
we set ρh
(j,k) = ρh(k,j) and all diagonal entries, i.e. the cor-
relation between treatment effects in the same stage, are
ρh(j,j) = 1.
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